Priveq invests in FrostPharma

FrostPharma welcomes Priveq Investment (“Priveq”) as a new growth partner

FrostPharma signed its first product agreements in 2017 and has since then launched over 50 products. Through strategic partnerships with pharmaceutical companies from Europe, USA and Asia a significant pipeline of new products has been secured covering a broad range of disease areas. While building a pharmaceutical company with a hospital and specialty pharma focus, FrostPharma has also developed a proprietary portfolio under the tradename Woodsafe. Woodsafe is a risk waste product offering a 66% reduction of CO2 compared to the products currently used in the healthcare sector.

“FrostPharma has been successful in attaining new products proactively and fast delivered strong commercial results. We are impressed by the founders and management team and thrilled to enter this partnership to accelerate the development together with them. As an investor with a strong ESG agenda we also very much look forward to contribute to the success of Woodsafe, a product that has the potential to reduce CO2 emissions from the healthcare sector here and now“, says Karl-Johan Willén, Partner and Investment manager at Priveq.

With an established platform across the Nordic region and Baltics the plan is to continue investing in the organization and to further expand the product portfolio.

“We strongly believe that the partnership with Priveq will provide FrostPharma with opportunities for accelerated sustainable growth going forward. The Priveq team has confirmed a significant understanding of the FrostPharma business model throughout this process. They also bring a strong track-record of adding value in these partnerships. I very much look forward to working with Priveq and the entire FrostPharma team in this next exciting phase of the FrostPharma growth journey” says Fredrik Andersch, CEO at FrostPharma.

“From the start 2017 a pharmaceutical company with a strong commercial platform has been built from scratch, with all required pharma capabilities inhouse. FrostPharma now cover all Nordic markets and has effectively launched 50 products in just six years. We focus on hospital and specialty products that meet specific patient and healthcare needs, and the FrostPharma team is doing an extraordinary job in making this happen. It is now very exciting to take the next step for FrostPharma together with the support and knowledge of Priveq “, says Clas Lindbergson, Co-founder and Head of business development at FrostPharma.

EY Corporate Finance was advisor to FrostPharma’s shareholders throughout the process.

For more information, please contact:

Fredrik Andersch, CEO FrostPharma, +46 737 74 40 67, fredrik.andersch@frostpharma.com

Karl-Johan Willén, Partner Priveq, +46 709 50 88 25

karljohan.willen@priveq.se

About Priveq For 40 years, Priveq Investment has invested in profitable growth companies. The business concept is to generate value through long-term investments and active ownership in unlisted growth companies. Since 1983, approximately SEK 8 billion has been managed and Priveq Investment and its employees have carried out 135 investments and been involved in taking 29 companies to an IPO. The current portfolio will consist of 17 companies which has a total revenue of approximately SEK 7.7 billion and 2,650 employees. Some of the current portfolio companies are Ports Group, Metenova and Swemac. Behind Priveq Investment is essentially a number of long-term, institutional pension funds in the Nordics and Europe, for example Skandia Liv, Fourth AP fund, abrdn and Pantheon. Visit www.priveq.se for further information.

FROSTPHARMA ENTERS AGREEMENT WITH ADVICENNE FOR MARKETING AND DISTRIBUTION OF SIBNYAL® IN THE NORDIC

FrostPharma AB announces signature of an exclusive Distribution Agreement with Advicenne for marketing and distribution of Sibnayal® in Denmark, Finland, Norway, Iceland and Sweden. Under the terms of the agreement, FrostPharma will receive the exclusive rights to distribute and market Sibnayal® for the treatment of distal renal tubular acidosis (dRTA) in the Nordic countries including Denmark, Finland, Norway, Iceland and Sweden. Sibnayal® received marketing authorisation in the European Union in May 2021 as the first and only label-approved drug for the treatment of Distal Renal Tubular Acidosis (dRTA) in adults, adolescents, and children aged one year and older. Clas Lindbergson, Head of Business Development of FrostPharma stated: “We are proud to be partnering with Advicenne for the delivery of Sibnayal™ to patients and improve the lives of those suffering from Distal Renal Tubular Acidosis (dRTA). We look forward to working with them and to be continuing to expand our product portfolio in areas of high unmet need.” Didier Laurens, Chief Executive Officer of Advicenne, commented: “We are delighted to be partnering with FrostPharma, a leader in the commercialization of a broad range of products across many disease areas. This is Advicenne’s third partnership for the commercialization of Sibnayal™ in just over a few weeks and is testament of our Company’s momentum. We have found in FrostPharma a partner that shares our same goal: delivering life-changing treatments for patients in areas of huge unmet need and we are looking forward to working together.” About FrostPharma FrostPharma is an entrepreneurial Swedish pharmaceutical company specializing in the commercialization of value-added products. Since the start in 2017, FrostPharma has successfully commercialized a broad range of products across multiple disease areas, throughout the Nordic countries and beyond. The key to our success is using our extensive in-house commercialization competence to match specific patient and health care needs with relevant products. For further information about FrostPharma, please visit www.frostpharma.com About Advicenne Advicenne (Euronext: ADVIC) is a specialty pharmaceutical company founded in 2007, specializing in the development of innovative treatments in Nephrology. Its lead product SibnayalTM (ADV 7103) has received its Marketing Approval for distal renal tubular acidosis in EU and the UK. ADV 7103 is currently in late-stage development in cystinuria in Europe and in dRTA and cystinuria in the US. Headquartered in Paris, Advicenne has been listed on the Euronext Paris stock exchange since 2017 and was cross-listed on the Euronext Brussels stock exchange in 2019. For additional information see: https://advicenne.com/ CONTACTS FrostPharma AB Clas Lindbergson, Head of Business Development Phone: +46 706 581180  Email: clas.lindbergson@frostpharma.com

FrostPharma organisation announcement

During her tenure as CEO for FrostPharma AB, Cecilia Bröms-Thell has invested and prepared the FrostPharma business for accelerated growth while securing solid performance of the in-line portfolio. The Regulatory framework and the Commercial capabilities have been strengthened and FrostPharma is now in a position to leverage and maximise its pipe-line opportunities. Cecilia Bröms-Thell has however recently decided to explore new opportunities outside of FrostPharma why she has resigned as CEO. For a period of time Cecilia has however agreed to stay on as Chief Commercial Officer effective 1 january 2022. In this new role Cecilia Bröms-Thell will continue to strengthen the FrostPharma capabilities. “On behalf of FrostPharma and the Board I want to thank Cecilia Bröms-Thell for her significant contribution to the FrostPharma business as CEO and wish her good luck in her new role within FrostPharma as Chief Commercial Officer and later in her new role outside of Frost.” From the 1st of January 2022 Fredrik Andersch take the role of FrostPharma CEO. Fredrik Andersch brings extensive international experience to FrostPharma from senior business positions at pharmaceutical companies such as AstraZeneca and Meda. Fredrik Andersch has a proven track-record of delivering strong growth through complex organisations both in a Nordic and international setting, such as Europe and Asia. With his background Fredrik Andersch also strengthen FrostPharma business development capabilities. The experience to drive growth through both portfolio and geographic expansion will further strengthen FrostPharma in its growth journey. As Fredrik consulted for FrostPharma in 2021 he has in-depth understanding of the organisation and business model, which secure business continuity during the transition. “On behalf of FrostPharma and the Board I want to wish Fredrik Andersch good luck in his role of CEO, and I look forward to working with him going forward.” About Frost Pharma AB FrostPharma AB is an entrepreneurial Swedish pharmaceutical company specialized in commercialization of products creating value. Since the start in 2017, FrostPharma has successfully commercialized a broad range of products across multiple disease areas, covering all Nordic countries and beyond. Key to success is the ability to match specific patient- and healthcare needs with relevant products in relation to our extensive in-house commercialization competence. Tomas Guinchard Chairman of the Board